Sanofi Highlights Data From Blood Cancer Drug Sarclisa In New Diagnosed Multiple Myeloma Patients
Portfolio Pulse from Vandana Singh
Sanofi SA (NASDAQ:SNY) shared positive data from the IMROZ phase 3 study of Sarclisa in newly diagnosed, transplant-ineligible multiple myeloma patients. The study showed significant improvements in progression-free survival and complete response rates. The FDA has accepted a supplemental application for Priority Review, and a regulatory submission is under review in the EU.
June 04, 2024 | 7:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sanofi's IMROZ phase 3 study of Sarclisa showed significant improvements in progression-free survival and complete response rates in multiple myeloma patients. The FDA has accepted a supplemental application for Priority Review, and a regulatory submission is under review in the EU.
The positive data from the IMROZ phase 3 study and the FDA's acceptance of the supplemental application for Priority Review are likely to boost investor confidence in Sanofi. The potential approval of Sarclisa for a new indication could drive future revenue growth.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100